Press Releases
Breaking News From Soin Neuroscience
Dr. Amol Soin Is Interviewed On Local Dayton TV
Watch the interview of Dr. Amol Soin on Fox 45 in Dayton as he explains our new experimental diabetic pain...
Hillsboro doctor develops new experimental diabetic neuropathy treatment
Highland County Press Dr. Amol Soin, Medical Director of the Ohio Pain Clinic, with an office in Hillsboro, has announced...
Dayton-area entrepreneur on cusp of ‘billion-dollar’ product (Exclusive)
by Tristan Navera Dayton Business Journal - Febuary 4, 2015 Dr. Amol Soin is setting his sights on a new...
TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients
CLEVELAND, Sept. 20, 2011 /PRNewswire/ -- TheraVasc (www.theravasc.com) announced the successful completion of a Phase I clinical trial of a...
TheraVasc’s clinical trial of PAD drug shows safety in diabetic patients
A phase 1 trial of a peripheral artery disease drug candidate from TheraVasc demonstrated safety in diabetic patients. The positive...
Startup Stories: A Race for Better Healing Therapies
Tony Giordano / President & CEO of TheraVasc - I am a molecular biologist with a Ph.D. from Ohio State...
Peripheral artery disease pill from TheraVasc heading to phase 2a trials
TheraVasc plans to begin enrolling patients this month in a phase 2a clinical trial of its pill designed to treat...
Peripheral artery disease drug developer TheraVasc raises $1.8M
TheraVasc Inc., which is reformulating a drug to treat vascular diseases, has raised $1.8 million in its first round of...
TheraVasc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum
Houston, TX, August, 19, 2009 - TheraVasc, LLC was named one of the most promising Life Science companies at the...
Reach Out To Us
Learn more about our current treatments now.
